GlassScriptPhysician profile
Anita R Scribner
NPI 1225005705
$77,909.38
in general payments reported to CMS, 2019-2025
46 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,100 · 2021: $36K · 2022: $16K · 2023: $2,406 · 2024: $5,248 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,242 · Travel and Lodging: $2,446 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,242.21 |
| Travel and Lodging | $2,445.85 |
| Education | $334.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $63,619.07 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $7,518.88 | 2019-2025 | Biktarvy, Epclusa, Sunlenca |
| Merck Sharp & Dohme LLC | $1,508.65 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Astellas Pharma US INC | $839.63 | 2019-2024 | |
| Abbvie INC. | $830.64 | 2019-2025 | Ubrelvy, Qulipta, Dalvance |
| Janssen Biotech, INC. | $511.15 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $388.89 | 2019-2025 | Nuzyra |
| Theratechnologies INC. | $297.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $213.93 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Products, LP | $198.00 | 2019-2020 | |
| Pfizer INC. | $183.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.13 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $153.36 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $144.97 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $122.14 | 2022-2025 |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Scribner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.